https://charts.traderzeitung.de/phases/US05153U1079
string(1396) "{"isin":"US05153U1079","name":"Aura Biosciences Inc","stock_id_xnas":22560339,"stock_id_xnys":null,"generated_at":"2026-09-24 01:31:00","days":[{"date":"2026-09-21","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":6.35,"close_at":"2026-09-21 21:59:00","complete":true,"perf_pct":null},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-09-22","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":6.46,"close_at":"2026-09-22 21:59:00","complete":true,"perf_pct":1.7323},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-09-23","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":6.02,"close_at":"2026-09-23 21:59:00","complete":true,"perf_pct":-6.8111},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":false,"perf_pct":null}]}]}"
Aura Biosciences Aktie News & Nachrichten
Trading-Room

Aura Biosciences Aktie News & Nachrichten

[WKN: A3C6D1 | Symbol: AURA]
Realtimekurs
   
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.
Vorbörsliche Indikationen
Regulärer Handel
Nachbörslicher Handel

Artikel aus der Redaktion der Trader-Zeitung

Aura Biosciences

TOP-5-Kursziele der Analysten am 18.10.24

H.C. Wainwright (18.10.24) Kursziel 14 USD (462 % Kurspotenzial) Gevo Inc. [US3743964062] Gevo...

  • ‹
  • 1
  • ›
Aura Biosciences Nachrichtenticker öffnen
MT Newswires 11.08.2026 13:33 Uhr

Aura Biosciences vergrößert Verlust im Q2

07:32 AM EDT, 11.08.2026 (MT Newswires) -- Aura Biosciences (AURA) meldete am Dienstag einen Verlust im Q2 von 0,48 $ je verwässerter Aktie, vergliche

MT Newswires 11.08.2026 13:21 Uhr

--Earnings Flash (AURA) Aura Biosciences meldet Nettoverlust im Q2 von 0,48 USD je Aktie, verglichen mit FactSet-Schätzung von 0,37 USD Verlust

07:19 AM EDT, 08/11/2026 (MT Newswires) -- http://www.mtnewswires.com Copyright © 2026 MT Newswires. All rights reserved. MT Newswires does not provid

MT Newswires 01.06.2026 14:40 Uhr

Aura Biosciences schließt Patientenrekrutierung in Phase-3-Studie von Belzupacap Sarotalocan bei frühem Aderhautmelanom ab

08:39 AM EDT, 06/01/2026 (MT Newswires) -- Aura Biosciences (AURA) teilte am Montag mit, dass es die Rekrutierung von 108 Patienten in einer Phase-3-S